



# Industry Updates

Bruce Rosenblum

VP Content and Workflow Solutions

# Agenda

- Industry Updates
- Accessibility
- When flawed implementation yields imperfect results: Following information crumbs
  - Data citations
  - Pagination woes
  - Author instructions (when personal meets professional)

# AI Run Amok: 2020 Edition

➤ <https://twitter.com/AlexanderRKlotz/status/1252389218514427909>

## [PDF] Lunch Menu

..., CS Salad, P Pack, B Noodles, C Fajitas, R **Beans**... - 2017 - rayusd.org

Thursday, February 2, 2017 Junior-Senior High School – HS Basketball @ Duncan HS –  
4:00/5:30/7:00 pm Junior-Senior High School – High School Spring Sports Participant Paperwork  
Due Friday, February 3, 2017 Junior-Senior High School – HS Basketball @ NFL Yet Prep ...

☆ 📄 All 29 versions 🔗

**Minor Leaguer** @Minor\_Leaguer · Apr 21

Replying to @AlexanderRKlotz and @wearyhobo

Do you think all these co-authors are family?

## Lunch Menu

M Sticks, BC Wings, LG Salad, LC Salad, LC Salad... - kitziesofspringmills.com

Kitzie's Sampler - Our Kitzie's fries topped with bacon, and cheese; 2 fried mozzarella cheese sticks and 2 chicken tenders - \$8.99 Kitzie's Crab Fries – a generous portion of crispy fries baked topped with lump crabmeat crispy bacon ... Mozzarella Sticks fried mozzarella cheese sticks ...

📄

# AI Run Amok: 2021 Edition

➤ <https://twitter.com/tsmullaney/status/1445869964695465987?cn=ZmxleGlibGVfcmVjcw%3D%3D&refsrc=email>



Tom Mullaney  
@tsmullaney



I write so many things these days it's hard to keep track. Could be mine? I'll need to go back over my files...

## ACADEMIA

Tom, is this publication yours? Help us keep your profile up to date.

Fatal Reactions In Bison  
Following Systemic  
Organophosphate Treatment  
for the Control of Hypoderma  
Bovis



Tom Mullaney

1991, Journal of Veterinary ...

# Unicode 14.0

- Released September 14, 2021
  - 838 new characters, including 37 new emoji
  - 144,697 total characters
  - 5 new scripts
  - Source: <http://www.unicode.org/versions/Unicode14.0.0/>



# Accessibility overlays (a warning)

➤ What's the little blue icon?

## Kitchen Product


Everyday tasks made easier. At American S  
kitchen faucets, sinks, and accessories that



MeasureFill



# Custom accessibility adjustments



- Implemented by adding one line in your HTML pages
- But does it work?

# Ask the expert

*“I was just on this website a consumer website and they have an interesting icon in the lower right corner of a person in a blue circle. If you click on the icon, you get a whole lot of controls for different kinds of disabilities to optimize the website. I’ve never seen this before. Is this part of the WCAG recommendations or something unique?”*

# The expert's reply

*You have stumbled upon the biggest controversy in the accessibility industry: accessibility overlays!*

*Given all the ADA litigation around website accessibility, some companies have sprung up that promise “instant, 100% ADA compliance” with just one line of code. (If that sounds like snake oil, you guessed it!)*

*The one on the consumer site is called AccessiBe and people have thoughts:*

[What's Wrong With Quick-Fix Products For Digital Accessibility \(forrester.com\)](#)

[Honor the ADA: Avoid Web Accessibility Quick-Fix Overlays – Law Office of Lainey Feingold \(llegal.com\)](#)

[Overlay Fact Sheet](#)

*So yes, quite the can of worms 😊*

# Accessibility is...

- Not free!
- Not easy!
- But important to do (ethically, and sometimes legally)
- We are here to help (<https://www.inera.com/blog/extyles-for-accessibility-part-1/>)
- And whatever you do... don't license accessibility overlays!

# Software citations

- JATS4R software citation recommendation
- Available for public comment until November 1
- <https://jats4r.org/software-citations/>

# Software citation ID challenges

- How do we know a reference is citing software?
  - Bates D et al. 2016. <https://cran.r-project.org/web/packages/lme4/index.html>
  - Rasband WS. 1997. Image J. US National Institutes of Health. <http://imagej.nih.gov/ij/>
  - Hannah N et al. 2019, April 12. The ACCESS-OM2 global ocean - sea ice coupled model (Version 1.0). Zenodo. <http://doi.org/10.5281/zenodo.2653246>

# Software citation ID challenges

- eXtyles identifies all of these as `<eref>` because there is no context to tell us they're citing software:

```
<eref>D. Bates et al., 2016. https://cran.r-project.org/web/packages/lme4/index.html</eref>
```

```
<eref>N. Hannah et al., 2019, April 12. The ACCESS-OM2 global ocean - sea ice coupled model (Version 1.0). Zenodo. http://doi.org/10.5281/zenodo.2653246</eref>
```

```
<eref>W. S. Rasband, 1997. Image J. US National Institutes of Health. http://imagej.nih.gov/ij/</eref>
```

- Authors usually don't provide sufficient context to auto-identify software citations
- Do you think vendors can get this right?

# Following information crumbs (1)...

- This data citation was not handled correctly at Crossref
  - Lerback, J., Hanson, B., & Wooden, P. (2020). *Data for "Association Between Author Diversity and Acceptance Rates and Citations in Peer-Reviewed Earth Science Manuscripts"*. Zenodo. <https://doi.org/10.5281/zenodo.3583354>
- The problem: The vendor mis-tagged a data citation as a book citation
- Mis-tagged data citations are a common problem
  - Authors fail to provide context
  - Vendors fail to research individual citations
- The challenge: mis-tagged data citations make it difficult to properly credit data

# Following information crumbs (2)...

- Atypon September 28 Minor release: Crossref deposit change for e-location IDs
- But Crossref supported deposit of e-location IDs as first-page for 20 years
- While an improvement, only needed for one customer. Why?
- The customer had e-location IDs like “e00332-20”
- Crossref has special code to parse first-page elements when publishers incorrectly placed a page range such as “332-345”

## ...to an answer

- But... Including hyphens (or most other punctuation) in e-location IDs contravenes best practices (and can also trip up eXtyles parsing)
- See <https://wayback.archive-it.org/12684/20190905184517/https://nfais.memberclicks.net/assets/docs/BestPractices/article%20publishing.pdf>
- *If article identifiers are used in a journal, they should be assigned in accord with the following:*
  - *They must contain at least 6 alpha and/or numeric characters so that they cannot be confused with pagination, volume number, or issue number.*
  - *They should contain no punctuation so that they cannot be confused with ISSNs, other similar identifiers, or page ranges.*

# Following information crumbs (3)...

- [https://www.wsj.com/articles/als-drug-works-in-study-researchers-say-11576558801?mod=searchresults\\_pos18&page=1](https://www.wsj.com/articles/als-drug-works-in-study-researchers-say-11576558801?mod=searchresults_pos18&page=1)

## ALS Drug Works in Study, Researchers Say

If promising data hold up, Amylyx Pharmaceuticals' drug could lead a wave of treatments for Lou Gehrig's disease



'I believe my ALS slowed down somewhat during the trial,' said Kristina Golji, pictured with her youngest son Reza in September. Ms. Golji was diagnosed in March 2017.

PHOTO: KRISTINA GOLJI

By [Jonathan D. Rockoff](#)

Dec. 17, 2019 12:00 am ET

 PRINT  TEXT

An experimental drug slowed the paralyzing march of amyotrophic lateral sclerosis, or Lou Gehrig's disease, in a clinical trial, according to researchers who say the results are a fresh sign that recent insights into the condition may soon bring new medicines.

# Published 9 months later in NEJM

➤ <https://www.nejm.org/doi/full/10.1056/NEJMoa1916945>

## Abstract

### BACKGROUND

Sodium phenylbutyrate and taurursodiol have been found to reduce neuronal death in experimental models. The efficacy and safety of a combination of the two compounds in persons with amyotrophic lateral sclerosis (ALS) are not known.



### ORIGINAL ARTICLE

## Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis

Sabrina Paganoni, M.D., Ph.D., Eric A. Macklin, Ph.D., Suzanne Hendrix, Ph.D., James D. Berry, M.D., Michael A. Elliott, M.D., Samuel Maiser, M.D., Chafic Karam, M.D., James B. Caress, M.D., Margaret A. Owegi, D.O., Adam Quick, M.D., James Wymer, M.D., Ph.D., Stephen A. Goutman, M.D., [et al.](#)

### RESULTS

A total of 177 persons with ALS were screened for eligibility, and 137 were randomly assigned to receive sodium phenylbutyrate–taurursodiol (89 participants) or placebo (48 participants). In a modified intention-to-treat analysis, the mean rate of change in the ALSFRS-R score was -1.24 points per month with the active drug and -1.66 points per month with placebo (difference, 0.42 points per month; 95% confidence interval, 0.03 to 0.81; P=0.03). Secondary outcomes did not differ significantly between the two groups. Adverse events with the active drug were mainly gastrointestinal.

participants with definite ALS who had  
participants were randomly assigned in a 2:1  
m phenylbutyrate and 1 g of  
(a day) or placebo. The primary  
phic Lateral Sclerosis Functional  
res indicating better function) through  
etric muscle strength, plasma  
low vital capacity; the time to death,  
tracheostomy, permanent ventilation,

# And a secondary study 6 weeks after

➤ <https://onlinelibrary.wiley.com/doi/10.1002/mus.27091>

**MUSCLE  
& NERVE**

CLINICAL RESEARCH ARTICLE | [Open Access](#) | 

## Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis

Sabrina Paganoni MD, PhD , Suzanne Hendrix PhD, Samuel P. Dickson PhD, Newman Knowlton MS, Eric A. Macklin PhD, James D. Berry MD, Michael A. Elliott MD, Samuel Maiser MD, ... [See all authors](#) 

First published: 16 October 2020 | <https://doi.org/10.1002/mus.27091> | Citations: 10

Portions of this manuscript were presented at the 2020 Annual Northeast Amyotrophic Lateral Sclerosis Consortium Meeting.

**Funding information:** ALS Finding A Cure Foundation; Amylyx Pharmaceuticals, Inc.; The ALS Association

### Abstract

An orally administered, fixed-dose coformulation of sodium phenylbutyrate-taurursodiol (PB-TURSO) significantly slowed functional decline in a randomized, placebo-controlled, phase 2 trial in ALS (CENTAUR). Herein we report results of a long-term survival analysis of participants in CENTAUR. In CENTAUR, adults with ALS were randomized 2:1 to PB-TURSO or placebo. Participants completing the 6-month (24-week) randomized phase were eligible to receive PB-TURSO in the open-label extension. An all-cause mortality analysis (35-month maximum follow-up post-randomization) incorporated all randomized participants. Participants and site investigators were blinded to treatment assignments through the duration of follow-up of this analysis. Vital status was obtained for 135 of 137 participants originally randomized in CENTAUR. Median overall survival was 25.0 months among participants originally randomized to PB-TURSO and 18.5 months among those originally randomized to placebo (hazard ratio, 0.56; 95% confidence interval, 0.34-0.92;  $P = .023$ ). Initiation of PB-TURSO treatment at baseline resulted in a 6.5-month longer median survival as compared with placebo. Combined with results from CENTAUR, these results suggest that PB-TURSO has both functional and survival benefits in ALS.

# High Altmetric score

MUSCLE  
& NERVE

CLINICAL RESEARCH ARTICLE |  Open Access | 

## Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis

Sabrina Paganoni MD, PhD , Suzanne Hendrix PhD, Samuel P. Dickson PhD, Newman A. Macklin PhD, James D. Berry MD, Michael A. Elliott MD, Samuel Maiser MD, ... See all

First published: 16 October 2020 | <https://doi.org/10.1002/mus.27091> | Citations: 10

Portions of this manuscript were presented at the 2020 Annual Northeast Amyotrophic Lateral Sclerosis Consortium Meeting.

**Funding information:** ALS Finding A Cure Foundation; Amylyx Pharmaceuticals, Inc.; T

um phenylbutyrate-taurursodiol  
ndomized, placebo-controlled,  
of a long-term survival analysis

Figures References Related **Information**

**Metrics**

Citations: 10

 score 295

**Details**

-  Picked up by **33** news outlets
-  Blogged by **5**
-  Tweeted by **52**
-  On **1** Facebook pages
-  Referenced in **2** Wikipedia pages
-  **59** readers on Mendeley

[See more details](#)

# But... Why is important information supplemental?

**MUSCLE & NERVE**

CLINICAL RESEARCH ARTICLE | [Open Access](#) |

## Long-term survival of participants in the CENT sodium phenylbutyrate-taurursodiol in amyot sclerosis

Sabrina Paganoni MD, PhD Suzanne Hendrix PhD, Samuel P. Dickson P A. Macklin PhD, James D. Berry MD, Michael A. Elliott MD, Samuel Maiser M

First published: 16 October 2020 | <https://doi.org/10.1002/mus.27091> |

Portions of this manuscript were presented at the 2020 Annual Northeast Consortium Meeting.

**Funding information:** ALS Finding A Cure Foundation; Amylyx Pharmaceu

### Supporting Information

Filename	Description
<a href="#">mus27091-sup-0001-supinfo.docx</a> Word 2007 document , 37.7 KB	<b>APPENDIX S1.</b> Supporting information
<a href="#">mus27091-sup-0002-FigureS1.pdf</a> PS document, 71.9 KB	<b>FIGURE S1</b> Duration of PB-TURSO exposure for each randomized participant. Each bar represents an individual participant, with grouping of bars by originally randomized treatment (PB-TURSO or placebo). PB-TURSO, sodium phenylbutyrate-taurursodiol.
<a href="#">mus27091-sup-0003-TableS1.docx</a> Word 2007 document , 44 KB	<b>TABLE S1</b> Participants' demographics and clinical characteristics <sup>a</sup>

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

# Ask the researcher... Print... Really?

- *Q: Your article has 2 figures and a table, and then a supplementary figure and a supplementary table. Clinical Research Articles in Muscle & Nerve allow up to 8 figures and tables. What was your rationale for making those 2 items supplementary rather than part of the article?*
- *A: We generally submit a few figures/tables (the number is always within Journal's guidelines but then reviewers/editors oftentimes make recommendations and most of the times they recommend to move content to the supplement - **I always assumed this is because they want to save space in the print version**)*

# Journal author instructions

- [https://onlinelibrary.wiley.com/pb-assets/assets/10974598/MUS\\_IFA%202021-1605546759153.pdf](https://onlinelibrary.wiley.com/pb-assets/assets/10974598/MUS_IFA%202021-1605546759153.pdf)

1 / 8 | - 150% +




**MUSCLE & NERVE**  
**INSTRUCTIONS *for* AUTHORS**

**Manuscript Categories and Requirements**

# What is “fast save”?

➤ [https://onlinelibrary.wiley.com/pb-assets/assets/10974598/MUS\\_IFA%202021-1605546759153.pdf](https://onlinelibrary.wiley.com/pb-assets/assets/10974598/MUS_IFA%202021-1605546759153.pdf)



## Guidelines for electronic submission

- Microsoft Word .doc or .docx files are required.
- Refrain from complex formatting; the Publisher will style your manuscript according to the Journal design specifications.
- Do not use desktop publishing software. If you prepared your manuscript with one of these programs, export the text to a word processing format.
- Please make sure your word processing program’s “fast save” feature is turned off.
- Do not deliver files that contain hidden text: for example, do not use your word processor’s automated features to create footnotes or reference lists.
- Submit the text and tables of each manuscript as a single file.
- Name each file with your last name (up to eight letters).
- Text files should be given the three-letter extension that identifies the file format.
- Macintosh users should maintain the MS-DOS “eight dot three” file-naming convention.

# Two weeks later, another ALS article

➤ <https://onlinelibrary.wiley.com/doi/10.1002/mus.27110>

**MUSCLE  
& NERVE**

CLINICAL RESEARCH SHORT REPORT | [Open Access](#) | 

## Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALS

Anna L. Beukenhorst PhD, Ella Collins BS, Katherine M. Burke DPT, Syed Minhajur Rahman BS, Margaret Clapp BA, Sai Charan Konanki MS, Sabrina Paganoni MD, PhD, ... [See all authors](#) ▾

First published: 29 October 2020 | <https://doi.org/10.1002/mus.27110>

### OpenURL

Anna L. Beukenhorst and Ella Collins contributed equally to this study.

Jukka-Pekka Onnela and James D. Berry contributed equally to this study.

**Funding information:** Philanthropic Support

### Abstract

#### Introduction

Passive data from smartphone sensors may be useful for health-care research. Our aim was to use the coronavirus disease-2019 (COVID-19) pandemic as a positive control to assess the ability to quantify behavioral changes in people with amyotrophic lateral sclerosis (ALS) from smartphone data.

#### Methods

Eight participants used the Beiwe smartphone application, which passively measured their location during the COVID-19 outbreak. We used an interrupted time series to quantify the effect of the US state of emergency declaration on daily home time and daily distance traveled.

#### Results

After the state of emergency declaration, median daily home time increased from 19.4 (interquartile range [IQR], 15.4-22.0) hours to 23.7 (IQR, 22.2-24.0) hours and median distance traveled decreased from 42 (IQR, 13-83) km to 3.7 (IQR, 1.5-10.3) km. The participant with the lowest functional ability changed behavior earlier. This participant stayed at home more and traveled less than the participant with highest functional ability, both before and after the state of emergency.

#### Discussion

We provide evidence that smartphone-based digital phenotyping can quantify the behavior of people with ALS. Although participants spent large amounts of time at home at baseline, the COVID-19 state of emergency declaration reduced their mobility further. Given participants' high level of daily home time, it is possible that their exposure to COVID-19 could be less than that of the general population.

# Accepted, despite significant style deviations

Smartphone data during the COVID-19 pandemic can quantify behavioral changes in people with ALS

Authors:

Anna L. Beukenhorst\*<sup>1</sup>, PhD  
Ella Collins\*<sup>2</sup>  
Katherine M. Burke<sup>2</sup>, DPT  
Syed Minhajur Rahman<sup>2</sup>  
Margaret Clapp<sup>3</sup>, BA  
Sai Charan Konanki<sup>1</sup>  
Sabrina Paganoni<sup>2,4</sup>, MD, PhD  
Timothy M. Miller<sup>3</sup>, MD, PhD  
James Chan<sup>5</sup>, MA  
Jukka-Pekka Onnela\*\*<sup>1</sup>, PhD  
James D. Berry\*\*<sup>2</sup>, MD

**Corresponding Author:**

James D. Berry, MD, MPH  
Healey Center for ALS  
Massachusetts General Hospital  
165 Cambridge St, Suite 600  
Boston, MA 02114  
Ph: (617) 726-5097  
Fax: (617) 724-7290  
Email: [jdberry@mgh.harvard.edu](mailto:jdberry@mgh.harvard.edu)

<sup>1</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts;

<sup>2</sup>Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, Massachusetts

<sup>3</sup>Department of Neurology, Washington University, Saint Louis, Missouri

<sup>4</sup>Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts

<sup>5</sup>Massachusetts General Hospital, Biostatistics Center, Harvard Medical School, Boston, Massachusetts

\*These authors contributed equally to the manuscript.

\*\*These authors contributed equally to the manuscript.

Study Funding : Philanthropic support

Accepted Article

# Ask the researcher, again

- *I can't make the interactions between authors and peer reviewers smoother or faster. But there are other things that I can work on with respect to publishing research. Can you list 3 things that you would love to see improved/changed in the process of writing and submitting articles, and having your research published? **Think big! If you can dream it, I can suggest it to my colleagues.***

# “What really drags an investigator down...”

- *What would clearly accelerate the dissemination of research is to have help with the administrative aspects. It would be wonderful if we could just submit the content in decent format and have [the publisher] take care of the details*
  1. *What really drags an investigator down is the formatting which differs from journal to journal and is extremely detailed and at times hard to figure out. **For example, it has happened to me in the past that it took me days/weeks to submit because I just didn't have time to format** (page numbering style, margins, font size, where to put the list of abbreviations, what to include on the title page and in what order etc)*
  2. *Not to mention **my fights with Scholar One** or whatever submission system (for example, entering every co-author affiliation one by one etc)*

# More researcher publication challenges

- *Other things that considerably slow down dissemination of research results*
  1. *Creation of high quality illustrations and tables. Could [publishers] offer assistance? That takes hours (generally nights and weekends)*
  2. *References. If authors had editorial help that would speed up the publication process – EndNote is very time consuming*
  3. *Point by point response to reviewers takes forever. I understand why they are important but I always tend to submit my reviews close to the deadline because it takes a long time to draft the point by point review, create the redline + clean copy. Not sure how to improve this but it takes up considerable time. maybe some help to format it?*

# The pernicious price of formatting

➤ <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223116>

## Conclusions

To our knowledge, this is the first study to analyze the cost of manuscript formatting in scientific publishing. Our results suggest that scientific formatting represents a loss of 52 hours, costing the equivalent of US\$1,908 per researcher per year. These results identify the hidden and pernicious price associated with scientific publishing and provide evidence to advocate for the elimination of strict formatting guidelines, at least prior to acceptance.

PLO

OPEN ACCESS

RESEARCH ARTICLE

## Scientific sinkhole: The pernicious price of formatting

Allana G. LeBlanc , Joel D. Barnes, Travis J. Saunders, Mark S. Tremblay, Jean-Philippe Chaput

Published: September 26, 2019 • <https://doi.org/10.1371/journal.pone.0223116>

# What's really important?

- Would you rather see a researcher spend 52 hours per year:
  - Reformatting manuscripts according to formatting guidelines
  - Creating life-saving medicines
  - Trying to understand global warming
- It's time, *now*, for all journals to become format neutral on submission
- It's the science that's important, not the formatting!
- Author guidelines should :
  - Outline content requirements, not formatting minutia
  - Be reviewed and updated annually
  - Remove any instruction that is handled automatically in editorial/production

# Thoughtful publication processes

- Look at the big picture
- Create and innovate thoughtfully
- Treat metadata with special care
  - QA, QA, QA!
  - Follow standards and best practices!
- Discard legacy workflows
- Update workflows for today's reality, not yesterday's print

# Thank you!

#XUG2021